%0 Journal Article %J Biomaterials %D 2022 %T Inflammation-specific targeted carriers for local drug delivery to inflammatory bowel disease. %A Kotla, Niranjan G %A Singh, Rajbir %A Baby, Becca V %A Rasala, Swetha %A Rasool, Jawad %A Hynes, Sean O %A Martin, Darrell %A Egan, Laurence J %A Vemula, Praveen K %A Jala, Venkatakrishna R %A Rochev, Yury %A Pandit, Abhay %X

Delivering drugs directly to the inflamed intestinal sites to treat inflammatory bowel disease (IBD), particularly Crohn's and ulcerative colitis, is highly challenging. Recent advances in colitis therapy medications are expanding opportunities for improving local on-site drug availability by minimising the associated systemic side-effects. Drug delivery with targeted carrier systems has shown the potential to increase site-specificity, stability, and therapeutic efficacy. Herein, we report the development of a strong anionic charged inflammation targeted nanocarriers (IT-NCs) loaded with an immunosuppressant model drug. This system showed preferential adhesion on a charge-modified surface in vitro, and in both dextran sulfate sodium (DSS) and TNBS colitis mice in vivo models. IT-NCs showed improved colitis phenotype therapeutic efficacy in both animal models compared to free drug. Furthermore, ex vivo study of colon tissue biopsies from patients with colitis revealed that IT-NCs adhered preferentially to inflamed biopsies compared to normal. Together, our results suggest that IT-NCs have promising therapeutic potential as delivery carriers' in colitis management.

%B Biomaterials %V 281 %P 121364 %8 2022 Jan 05 %G eng %R 10.1016/j.biomaterials.2022.121364 %0 Journal Article %J Nat Commun %D 2019 %T Enhancement of the gut barrier integrity by a microbial metabolite through the Nrf2 pathway. %A Singh, Rajbir %A Chandrashekharappa, Sandeep %A Bodduluri, Sobha R %A Baby, Becca V %A Hegde, Bindu %A Kotla, Niranjan G %A Hiwale, Ankita A %A Saiyed, Taslimarif %A Patel, Paresh %A Vijay-Kumar, Matam %A Langille, Morgan G I %A Douglas, Gavin M %A Cheng, Xi %A Rouchka, Eric C %A Waigel, Sabine J %A Dryden, Gerald W %A Alatassi, Houda %A Zhang, Huang-Ge %A Haribabu, Bodduluri %A Vemula, Praveen K %A Jala, Venkatakrishna R %K Animals %K Basic Helix-Loop-Helix Transcription Factors %K Caco-2 Cells %K Coumarins %K Epithelial Cells %K Gene Expression Regulation %K HT29 Cells %K Humans %K Intestinal Mucosa %K Macrophages %K Mice %K Mice, Inbred C57BL %K Mice, Knockout %K NF-E2-Related Factor 2 %K Receptors, Aryl Hydrocarbon %K Specific Pathogen-Free Organisms %K Tight Junction Proteins %X

The importance of gut microbiota in human health and pathophysiology is undisputable. Despite the abundance of metagenomics data, the functional dynamics of gut microbiota in human health and disease remain elusive. Urolithin A (UroA), a major microbial metabolite derived from polyphenolics of berries and pomegranate fruits displays anti-inflammatory, anti-oxidative, and anti-ageing activities. Here, we show that UroA and its potent synthetic analogue (UAS03) significantly enhance gut barrier function and inhibit unwarranted inflammation. We demonstrate that UroA and UAS03 exert their barrier functions through activation of aryl hydrocarbon receptor (AhR)- nuclear factor erythroid 2-related factor 2 (Nrf2)-dependent pathways to upregulate epithelial tight junction proteins. Importantly, treatment with these compounds attenuated colitis in pre-clinical models by remedying barrier dysfunction in addition to anti-inflammatory activities. Cumulatively, the results highlight how microbial metabolites provide two-pronged beneficial activities at gut epithelium by enhancing barrier functions and reducing inflammation to protect from colonic diseases.

%B Nat Commun %V 10 %P 89 %8 2019 01 09 %G eng %N 1 %R 10.1038/s41467-018-07859-7 %0 Journal Article %J Adv Drug Deliv Rev %D 2018 %T Bioresponsive drug delivery systems in intestinal inflammation: State-of-the-art and future perspectives. %A Kotla, Niranjan G %A Rana, Shubhasmin %A Sivaraman, Gandhi %A Sunnapu, Omprakash %A Vemula, Praveen K %A Pandit, Abhay %A Rochev, Yury %X

Oral colon-specific delivery systems emerged as the main therapeutic cargos by making a significant impact in the field of modern medicine for local drug delivery in intestinal inflammation. The site-specific delivery of therapeutics (aminosalicylates, glucocorticoids, biologics) to the ulcerative mucus tissue can provide prominent advantages in mucosal healing (MH). Attaining gut mucosal healing and anti-fibrosis are main treatment outcomes in inflammatory bowel disease (IBD). The pharmaceutical strategies that are commonly used to achieve a colon-specific drug delivery system include time, pH-dependent polymer coating, prodrug, colonic microbiota-activated delivery systems and a combination of these approaches. Amongst the different approaches reported, the use of biodegradable polysaccharide coated systems holds great promise in delivering drugs to the ulcerative regions. The present review focuses on major physiological gastro-intestinal tract challenges involved in altering the pharmacokinetics of delivery systems, pathophysiology of MH and fibrosis, reported drug-polysaccharide cargos and focusing on conventional to advanced disease responsive delivery strategies, highlighting their limitations and future perspectives in intestinal inflammation therapy.

%B Adv Drug Deliv Rev %8 2018 Jun 29 %G eng %R 10.1016/j.addr.2018.06.021